



## **Adverum Biotechnologies Presents at the Piper Sandler Annual Virtual Healthcare Conference**

November 23, 2020

REDWOOD CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- [Adverum Biotechnologies, Inc.](#) (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company's presentation at the Piper Sandler 32<sup>nd</sup> Annual Virtual Healthcare Conference.

Adverum's video webcast will be accessible on demand beginning today at 10:00 am ET under [Events and Presentations](#) in the Investors section of the company's website. This webcast will be available on the Adverum website for 30 days.

### **About Adverum Biotechnologies**

Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit [www.adverum.com](http://www.adverum.com).

Investor and Media Inquiries: Myesha Lacy Adverum Biotechnologies, Inc. [mlacy@adverum.com](mailto:mlacy@adverum.com) 1-650-649-1257